INTRODUCTION
Dengue, an acute febrile illness characterized by fever, headache, eye pain, myalgia, arthralgia, hemorrhage, and rash, 1 is a leading cause of febrile illness among travelers returning from the Caribbean. 2, 3 Dengue is caused by the bite of an Aedes aegypti or Ae. albopictus mosquito 4, 5 infected with one of four dengue viruses (DENV-1, -2, -3 and -4) that belong to the viral family Flaviviridae . Because there is currently no effective antiviral drug or vaccine available to treat or prevent dengue, 6, 7 minimizing mosquito exposure while traveling is the most effective means of preventing infection. 8, 9 Although no consistent surveillance for dengue exists in Haiti, mosquito vectors for dengue are present in Haiti, 10 and dengue has been documented in visitors to Haiti, including travelers, 11, 12 military personnel, 13 and relief workers. 14, 15 These observations, along with reports of dengue in native Haitians, [16] [17] [18] [19] suggest that DENV transmission is endemic in Haiti.
After the 2010 Haiti earthquake, the Centers for Disease Control and Prevention (CDC) issued a briefing on dengue in Haiti as part of the emergency response plan after a volunteer returning from Haiti in January of 2010 with denguelike symptoms was confirmed to be infected with DENV. 20 The patient worked for a charity organization in Port-auPrince and reported having slept outside after the earthquake (CDC, unpublished data). CDC also issued a Health Alert Network advisory asking US physicians to be vigilant and report suspected cases of dengue among relief workers returning from Haiti. 21 The Nebraska Department of Health and Human Services was notified by Nebraska's Central District Health Department in October of 2010 of a cluster of dengue-like illness among members of a missionary group recently returned from Haiti. The goals of this investigation were to (1) describe the clinical and laboratory characteristics of DENV-infected and non-infected travelers to Haiti, (2) describe pre-travel knowledge about dengue risk and methods to prevent disease, and (3) identify risk factors for DENV infection.
MATERIALS AND METHODS

Background.
A group of 28 missionaries from Nebraska ( n = 22) and Georgia ( n = 6) traveled to the Carrefour region of Haiti in October of 2010, where they stayed in a house with non-closing/non-screened windows, no air conditioning, and intermittent electricity. Twenty-two travelers spent 7 days, three travelers spent 9 days, and three travelers spent 11 days in Haiti. The travelers provided humanitarian assistance while in Haiti, which included offering spiritual and community support, prayer walks, and organizing activities such as food drives, medical clinics, religious classes, and soccer games. Most activities were conducted during the daytime within walking distance of the house where the travelers stayed; most morning group meetings were conducted inside a nearby building, and evening group meetings were conducted on a nearby rooftop.
Laboratory methods. All travelers of the returning missionary group were offered laboratory testing for DENV infection by the CDC Dengue Branch diagnostic laboratory. Separate testing algorithms were used for travelers reporting any sign or symptom of illness during travel or within 14 days of returning home (i.e., symptomatic travelers) and travelers not reporting illness (i.e., non-ill travelers). For symptomatic travelers, specimens collected within 5 days of illness onset were considered acute, and specimens collected after 5 days of illness onset were considered convalescent. For non-ill travelers, because the period of viremia and the immune response in asymptomatic infections is not well-understood, 22 paired specimens were requested: first specimens were collected within 8 days of returning home, and second specimens were collected at least 14 days after the first specimen.
Diagnostic testing. Acute and first specimens were tested by real-time reverse transcription polymerase chain reaction (rRT-PCR) using DENV serotype-specific primers. 23 Acute or first specimens testing negative by rRT-PCR were subsequently tested by anti-DENV immunoglobulin M (IgM) antibody capture enzyme-linked immunosorbent assay Abstract. Dengue is an acute febrile illness caused by four mosquito-borne dengue viruses (DENV-1 to -4) that are endemic throughout the tropics. After returning from a 1-week missionary trip to Haiti in October of 2010, 5 of 28 (18%) travelers were hospitalized for dengue-like illness. All travelers were invited to submit serum specimens and complete questionnaires on pre-travel preparations, mosquito avoidance practices, and activities during travel. DENV infection was confirmed in seven (25%) travelers, including all travelers that were hospitalized. Viral sequencing revealed closest homology to a 2007 DENV-1 isolate from the Dominican Republic. Although most (88%) travelers had a pre-travel healthcare visit, only one-quarter knew that dengue is a risk in Haiti, and one-quarter regularly used insect repellent. This report confirms recent DENV transmission in Haiti. Travelers to DENV-endemic areas should receive dengue education during pre-travel health consultations, follow mosquito avoidance recommendations, and seek medical care for febrile illness during or after travel.
(MAC-ELISA), 24 and a convalescent or second specimen was requested and tested by MAC-ELISA. To identify additional cases, convalescent or second specimens were screened for anti-DENV IgG antibody at a dilution of 1:100. 25, 26 Because 50-80% of DENV infections can be asymptomatic, 22, 27, 28 anti-DENV IgG titers to detect seroconversion were determined on paired specimens positive at the screening dilution for symptomatic and non-ill travelers.
Laboratory definitions. Acute DENV infection was defined as a traveler with (1) any specimen testing positive by rRT-PCR or (2) paired specimens showing a fourfold or greater rise in anti-DENV IgG antibody with a 90% reduction in plaques in the specimen compared with the virus control in a plaque reduction neutralization test (PRNT 90 ) that confirmed specificity of antibodies against DENV. 29 No acute DENV infection was defined as a traveler with a convalescent or second specimen that tested negative by MAC-ELISA. Indeterminate DENV infection was defined as a traveler with a negative MAC-ELISA and rRT-PCR in the acute or first specimen with no convalescent or second specimen provided. A recent flavivirus infection was defined as a traveler with any specimen testing positive by MAC-ELISA.
Prior flavivirus exposure was defined as detection of anti-DENV IgG antibodies in an acute or first specimen. Because of known antibody cross-reactivity between flaviviruses, 30 paired specimens from travelers with prior flavivirus exposure were tested by PRNT 90 against DENV-1 to -4 and West Nile virus (WNV) to confirm prior flavivirus exposure.
Case definitions. A dengue case was defined as a symptomatic traveler with an acute DENV infection. A dengue non-case was defined as a traveler with no acute DENV infection. Dengue fever and severe dengue were defined according to the 2009 World Health Organization (WHO) guidelines.
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Epidemiologic investigation. All 28 travelers were invited to answer a 53-item questionnaire that collected information on the following topics: demographics; medical, vaccination (i.e., against yellow fever virus [YFV] or Japanese encephalitis virus [JEV]), and travel history; pre-travel preparation and knowledge of dengue; living arrangements while in Haiti; prevention activities used while in Haiti; and illness during travel or within 14 days of returning home. Travelers were subsequently asked to answer an 18-item supplementary questionnaire regarding participation in specific activities while in Haiti. Dengue case investigation forms (DCIFs; available at http://www.cdc.gov/Dengue/resources/TestpolEng_2.pdf ) were completed for each traveler providing a serum specimen, and it recorded demographic, epidemiologic, and clinical information. Additional clinical course data was obtained from hospital discharge summaries. Initial and supplemental questionnaires were completed within 8 weeks of returning home. All travelers who had laboratory evidence of prior flavivirus exposure were asked if they recalled a prior flavivirus diagnosis (i.e., WNV, YFV, JEV, Saint Louis encephalitis virus, Murray Valley encephalitis virus, tick-borne encephalitis virus, or any other flavivirus). If a prior flavivirus diagnosis was reported, information regarding date of diagnosis, hospitalization status secondary to diagnosis, and symptoms associated with diagnosis were also collected.
Sequencing and phylogenetic analysis. Serum specimens were inoculated into cultured C6/36 ( Ae. albopictus ) cells, and the presence of virus was confirmed by rRT-PCR 23 and indirect immunofluorescence. Isolates were further propagated and viral RNA was extracted from culture supernatant using the Universal BioRobot System (Qiagen, Valencia, CA). The envelope glycoprotein (E) gene was amplified and sequenced; sequence data were restricted to the E gene open-reading frame (1,485 base pairs). Multiple sequence alignment was performed using the ClustalW module available in MEGA 5 (www.megasoftware.net). Evolutionary history was inferred using neighbor-joining trees. Evolutionary distances were computed , and several E gene sequences from GenBank were included in the phylogenetic tree to support tree topology by genotype ( Supplemental Table 1 ).
Study design and statistical analyses. A retrospective cohort study was performed to identify differences between dengue cases and non-cases. This study underwent CDC human participants review and was determined to be public health practice and not research; as such, Institutional Review Board approval was not required. All travelers with indeterminate test results or who did not provide a serum specimen for diagnostic testing were excluded from analysis. Data were analyzed using SAS 9.2 (SAS Institute Inc., Cary, NC). Fisher exact test was used to calculate P values to test the statistical significance of association (α = 0.05) between pre-travel dengue knowledge, mosquito avoidance practices, or participation in specific activities and acute DENV infection.
RESULTS
Identification of acute DENV infections.
Of the 28 travelers, clinical information was available for 26 (93%), and 23 (82%) provided at least one serum specimen for diagnostic testing. Eighteen (69%) travelers reported any illness during travel or within 14 days of returning home. Seven (39%) of those travelers had an acute DENV infection, nine (50%) had no acute DENV infection, and one (6%) had indeterminate diagnostic testing; one (6%) symptomatic traveler did not provide a specimen. Of eight non-ill travelers, five (63%) had no acute DENV infection, and one (13%) had indeterminate diagnostic testing; two (25%) non-ill travelers did not provide a specimen. Thus, of 28 travelers, 7 (25%) had an acute DENV infection, 14 (50%) had no acute DENV infection, 2 (7%) had an indeterminate test result, and 5 (18%) did not provide a serum specimen.
Demographic characteristics. Twenty-five (89%) of twentyeight travelers provided demographic information ( Table 1 ) . Fourteen (56%) were male, all were white and non-Hispanic, and the median age was 34 years (range = 11-69 years). All were born in the continental United States. More than onehalf had previously traveled outside of the continental United States, including two (8%) with previous travel to Haiti; six (24%) had previously lived in a DENV-endemic country. No travelers reported prior DENV infection. Six (24%) travelers reported having been vaccinated against YFV, and none reported vaccination against JEV.
Prior flavivirus exposure. Seven travelers met the case definition for prior flavivirus exposure ( Table 2 ) Clinical course. Of the seven travelers with acute DENV infection, all met the 2009 WHO criteria for dengue; none met the criteria for severe dengue. 1 All dengue cases had fever, chills, myalgia /body pain, eye pain, arthralgia/joint pain, anorexia, and weakness. Other signs and symptoms among these seven travelers included headache, rash, nausea/vomiting, lethargy/ restlessness, abdominal pain, and hemorrhagic manifestations such as petechiae, purpura, and menorrhagia ( Table 3 ). All had illness onset 3-7 days (median = 4 days) after returning home, and all sought medical care. Five (71%) of seven dengue cases required hospitalization for fluid management and close monitoring of fever, thrombocytopenia, leucopenia, and/or hemorrhagic manifestations. Cases were hospitalized for 3-5 days (median = 3 days) within 3-6 days (median = 5 days) of illness onset; none were admitted to an intensive care Each taxon represents a single virus isolate and is labeled with the geographical origin and collection year; an additional specimen identifier is also included in specimens isolated from travelers to Haiti. Eighteen E gene sequences obtained from GenBank were included to support tree topology and identify genotypes. Three major genotypes are marked by brackets: American/African, South Pacific, and Asian. Taxa labels and GenBank accession numbers are available in Supplemental Table 1 . unit, and all survived. The five hospitalized cases included the four DENV-infected travelers with evidence of prior flavivirus exposure and one of three DENV-infected travelers without evidence of prior flavivirus exposure.
Behavioral risk factors. An initial questionnaire was completed by 25 (89%) of 28 travelers. Twenty-two (88%) respondents sought pre-travel advice from a healthcare provider, all of whom recalled receiving malaria chemo prophylaxis and/or at least one vaccine (e.g., typhoid; hepatitis A; hepatitis B; poliovirus; tetanus, diphtheria, acellular pertussis; measles, mumps, and rubella; or influenza). Of the 22 travelers, sixteen (73%) recalled receiving information about health risks in Haiti, thirteen (59%) recalled receiving information about mosquito avoidance, and two (9%) recalled receiving information about dengue.
About one-half of travelers who completed the initial questionnaire reported pre-travel knowledge of dengue ( Table 4 ) ; however, less than one-third of travelers knew about potential dengue exposure while in Haiti. Less than one-half of respondents recalled being bitten by a mosquito while in Haiti, few reportedly used mosquito repellant appropriately, and less than one-half wore long pants on at least one occasion. There was no statistically significant difference between cases and non-cases in pre-travel dengue knowledge or mosquito avoidance practices.
Twenty-three (92%) of twenty-five travelers who completed the initial questionnaire also completed the supplemental questionnaire. All respondents attended at least one of the morning and evening group meetings and participated in at least one of two food drives. Most respondents participated in the twice daily prayer walks on at least one occasion, at least one of the daily religious classes, and at least one of the medical clinic sessions; few participated in one of two soccer tournaments. No statistically significant difference was found in participation in these activities between cases and non-cases.
DISCUSSION
This is the third published investigation of a cohort of travelers from the United States returning from the Caribbean with dengue, 31, 32 and the first report of dengue in Haiti after the earthquake in January of 2010. Although the group spent only 1 week in Haiti, at least 25% were acutely infected with DENV. This attack rate during short-term travel provides insight into the force of DENV transmission in Haiti and illustrates the need for pre-travel information about dengue and mosquito avoidance strategies for travelers to DENV-endemic areas to include education on dengue risks and prevention strategies.
In addition to living in a house with no window screens and limited use of mosquito avoidance practices, the high attack rate experienced by this group of travelers may be explained by increased dengue activity in the Caribbean in 2010 33 and/ or travel to Haiti during peak dengue season 16, 34 when vector populations are likely to be high. 35 Moreover, the findings from this report along with documented dengue cases among native Haitians, [16] [17] [18] [19] travelers to Haiti, [11] [12] [13] [14] [15] and known dengue endemicity in the neighboring Dominican Republic [36] [37] [38] indicate that Haitians and travelers to Haiti are at risk for DENV infection.
This report also illustrates recent circulation of DENV-1 in Haiti. All viruses identified by sequencing in this investigation were most closely related to a DENV-1 isolated in 2007 from the Dominican Republic and Puerto Rico, suggesting that the same virus was circulating on Hispaniola between at least 2007 and 2010. Previous studies have shown that DENV disseminates in the region rapidly but not fast enough to avert geographic clustering 39 ; therefore, the phylogenetic association between DENV-1 isolates from 2007 and 2010 is highly indicative of local and continuous evolution of this lineage. These observations together contribute to the evidence that suggests DENV is endemic in Haiti, although consistent surveillance is necessary to definitively make this conclusion. Although most travelers in this report had a pre-travel healthcare visit, many were unaware of the risk of acquiring dengue in Haiti and similar to previous reports, 31, 32 did not use mosquito avoidance practices. Healthcare providers involved in pre-travel consultations should be knowledgeable of dengue risk and prevention communication. 40 Travelers to DENV-endemic areas should be informed that risk of acquiring dengue can be reduced through use of effective mosquito avoidance practices such as the application of repellent and use of repellent-impregnated long-sleeved shirts and pants. 8, 9 Additionally, travel coordinators and other persons within the travel industry are in an advantageous position to educate travelers 41 and should remain up to date on destinationspecific dengue risks. Information about prevention measures and areas with recent DENV transmission are available in the CDC yellow book (available at wwwnc.cdc.gov/travel/yellowbook/2010) and Dengue Map (available at www.healthmap .org/dengue/index.php ).
Persons traveling to or returning from DENV-endemic areas should be advised to seek medical care if they develop a febrile illness during or after travel. Healthcare providers evaluating such travelers should consider dengue in their differential diagnosis and are encouraged to confirm the diagnosis by submitting appropriate specimens for dengue diagnostic testing. Additionally, because dengue is a reportable disease in the United States, suspected and confirmed dengue cases should be promptly reported to public health authorities. Given the existence of competent mosquito vectors within the United States and recent reports of autochthonous DENV transmission in the United States, 4, 42 timely public health notifications can facilitate risk assessment for secondary local DENV transmission.
This investigation was subject to at least four limitations. First, because of the timing and in some cases, lack of specimen collection, some dengue cases may have been missed, namely in asymptomatic individuals. Second, one traveler with an acute DENV-1 infection that had a low neutralizing antibody titer against DENV-1 in an acute specimen may have been misclassified as a prior flavivirus exposure; because this individual had no prior travel to a DENV-endemic region, this result may have been due to an early rise in IgG after DENV-1 infection. Third, severity of disease for hospitalized travelers may have been underestimated, because all symptoms of disease may not have been included in hospital discharge summaries used to collect clinical information. Fourth, the time between pre-travel healthcare visits, trip activities, or symptom onset and questionnaire administration may have resulted in recall bias.
This outbreak confirms the risk of dengue among travelers to Haiti, where the disease is likely endemic, and it highlights the need to more effectively educate travelers about dengue. Travelers to DENV-endemic areas should seek pre-travel medical consultation 4-6 weeks before travel and adhere to prevention strategies to avoid mosquito bites while traveling. Healthcare providers, travel coordinators, and pre-travel health information resources should tailor recommendations regarding dengue to travelers using up to date information provided on the aforementioned websites. Healthcare providers caring for febrile travelers returning from DENV-endemic regions should consider dengue in their differential diagnosis, submit specimens for laboratory testing, and report cases to local or state health departments.
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